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Abstract
Background:  Germ-line mutations in genes such as BRCA1,  BRCA2, and ATM  can cause a
substantial increase in risk of breast cancer. However, these mutations are rare in the general
population, and account for little of the incidence of sporadic breast cancer in the general
population. Therefore, research has been focused on examining associations between common
polymorphisms and breast cancer risk. To date, few associations have been described. This has led
to the hypothesis that breast cancer is a complex disease, whereby a constellation of very low
penetrance alleles need to be carried to present a risk phenotype. Polymorphisms in the manganese
superoxide dismutase (MnSOD) and glutathione peroxidase (GPX-1) genes have been proposed as
low penetrance alleles, and have not been clearly associated with breast cancer. We investigated
whether variants at both polymorphisms, while not independently associated with breast cancer
risk, could influence breast cancer risk when considered together.
Methods: A case-control study nested within the Nurses' Health Study was performed comparing
1262 women diagnosed with breast cancer to 1533 disease free women. The MnSOD (Val16Ala,
rs1799725) and GPX-1 (Pro198Leu, rs1050450) were genotyped via TaqMan assay. Disease risk
was evaluated using logistic regression.
Results: While neither allele alone shows any change in breast cancer risk, an increase in the risk
of breast cancer (OR 1.87, 95% CI 1.09 – 3.19) is observed in individuals who carry both the
Ala16Ala genotype of MnSOD and the Leu198Leu genotype of GPX-1.
Conclusion: Polymorphisms in the GPX-1 and MnSOD genes are associated with an increased risk
of breast cancer.
Background
Both manganese superoxide dismutase and glutathione
peroxidase act as antioxidant enzymes [1,2]. Non-synon-
ymous polymorphisms in both genes have been shown to
reduce their effectiveness at removing oxidative species
from cells [3,4]. Oxidative stress has been hypothesized to
be involved in breast cancer risk, and there is evidence
supporting a modest inverse association between levels of
antioxidants and breast cancer risk [5]. However, poly-
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morphisms in these two genes do not individually alter
breast cancer risk [6,7].
Few polymorphisms have shown statistically significant
associations with breast cancer risk to date. One explana-
tion for this lack of association could be that common
polymorphisms do not have a large enough effect on the
function of any particular gene to be responsible for can-
cer development alone. Rather, polymorphisms in several
biologically related genes which slightly modify the func-
tion of each individual gene, may combine to explain the
genetic component of breast cancer risk. Additionally,
lifestyle factors could also play a role in disease etiology,
either independently or in combination with genetic var-
iants.
We have previously genotyped non-synonymous poly-
morphisms in the MnSOD (Val16Ala, rs4880) and GPX-1
(Pro198Leu, rs1050450) genes, and found no association
between these individual polymorphisms and breast can-
cer risk [6,7]. However, given that both genes act as anti-
oxidants, we hypothesized that being homozygous for the
198Leu allele of GPX-1 which is less responsive to sele-
nium [3], and the 16Ala allele of MnSOD which is associ-
ated with increased urinary DNA adduct levels [4]
increases breast cancer risk.
Methods
Genotyping assays for the MnSOD (Val16Ala, rs1799725)
and GPX-1 (Pro198Leu, rs1050450) polymorphisms were
performed by the 5' nuclease assay (TaqMan) on the ABI
Prism 7900HT Sequence Detection System (Applied Bio-
systems, Foster City, CA). TaqMan primers, probes, and
conditions for genotyping assays are available on request
from the authors. Our study included a total of 1262 inci-
dent breast cancer cases diagnosed after blood draw up to
June 1, 2000, and 1533 matched controls, all drawn from
32,826 women in the Nurses' Health Study who gave a
blood sample in 1989–90. Controls were randomly
selected participants who were free of diagnosed cancer
(except non-melanoma skin cancer), and matched to
cases based on age, menopausal status, recent post-meno-
pausal hormone use, and time, day, and month of blood
collection. A detailed description of this study population
has been previously reported [8]. Approximately 95% of
the samples were successfully genotyped for each poly-
morphism individually; samples that failed genotyping
for both polymorphisms were removed from the analyses.
Internal blinded quality control samples (49 sets of repli-
cate samples, including from 2 to 9 replicates) showed
100% concordance.
We used SAS v9.1 (SAS Institute, Cary, NC) for all statisti-
cal analyses. Odds ratios (OR) and 95% confidence inter-
vals (CI) were calculated using unconditional logistic
regression, controlling for matching factors, age at meno-
pause, age at menarche, age at first birth and parity, body
mass index at age 18, weight gain since age 18, history of
benign breast disease, and family history of breast cancer
using PROC LOGISTIC. Interactions were tested by likeli-
hood ratio tests comparing the model with main effects
for each polymorphism to the model including indicator
variables for the cross-tabulation of the two polymor-
phisms. All p-values reported are two-sided. Power calcu-
lations were carried out using Quanto [9]. This study was
approved by the Institutional Review Board of Brigham
and Women's Hospital (protocol # 1999-P-001718).
Results and discussion
Table 1 shows the cross-tabulation of both the MnSOD
and GPX-1 genotypes and breast cancer risk. The distribu-
tion of the combined genotypes shown is not statistically
different from that expected, given the respective genotype
frequencies (Chi-squared = 3.14 with 1 d.f p = 0.08). Nei-
ther of these two SNPs individually increases breast cancer
risk. Given that these two genes are active on the pathway
of detoxification of reactive oxygen species (ROS) from O-
to H2O2 (MnSOD), and further to H2O (GPX-1) and these
polymorphisms influence the efficiency of this detoxifica-
tion, we hypothesized that risk could be detected when
the two SNPs are combined. In these analyses, the combi-
nation of the two polymorphisms is associated with sig-
nificantly increased breast cancer risk. Individuals
homozygous for the Ala16 allele of MnSOD and Leu198
Table 1: Interaction between GPX1 Pro198Leu and MnSOD Val16Ala polymorphisms and breast cancer risk in the Nurses' Health 
Study
Genotype Cases (%)* Controls (%)* OR (95% CI)**
Pro198 carrier and Val16 carrier 771 (67.0) 997 (67.4) 1.00 (Ref.)
Leu198Leu and Val16 carrier 90 (7.8) 124 (8.4) 0.94 (0.69 – 1.27)
Pro198 carrier and Ala16Ala 255 (22.2) 331 (22.4) 1.01 (0.83 – 1.23)
Leu198Leu and Ala16Ala 35 (3.0) 28 (1.9) 1.87 (1.09 – 3.19)
* Samples failing genotyping for both assays were removed from the analyses
** Unconditional logistic regression, controlled for fasting status, date and time of blood draw, age at blood draw (5 year categories), menopausal 
status, recent post-menopausal hormone use at blood draw, age at menopause, age at menarche, body mass index at age 18, weight gain since age 
18, age at fist birth/parity, history of benign breast disease, and family history of breast cancer. Interaction p-value = 0.03.BMC Cancer 2006, 6:217 http://www.biomedcentral.com/1471-2407/6/217
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allele of GPX-1 have a 1.87 fold increase in breast cancer
risk compared to Val16 and Pro198 carriers, and the p-
value for the interaction between these genotypes is 0.03.
Further in vitro or in vivo work should be carried out to
examine the differences in ROS levels in cells containing
variant GPX-1 and MnSOD alleles.
To date, few such interactions have been detected and
reported in the literature. Of major concern to studies
examining the interaction between multiple exposures
(either gene × gene or gene × environment) on disease risk
is study size. In order to have sufficient power to detect
such associations, large data sets are necessary. Our study
has 80% power to detect an odds ratio of 1.85 for an inter-
action between the recessive models for two polymor-
phisms such as those reported here, where neither
polymorphism alone increases risk. In the present analy-
ses, we benefit from the relatively high prevalence of the
two polymorphisms. If the prevalence of one or both pol-
ymorphisms was lower, very large studies would be
needed to detect an interaction similar to the one we
observed. Of obvious interest would be to examine more
genes along the same pathway, as well as non-genetic var-
iables such as plasma antioxidant levels or lifestyle factors
which affect oxidative stress such as cigarette smoking,
and consumption of alcohol, as well as dietary antioxi-
dants or supplements. However, including further varia-
bles would necessitate even larger sample size. Future
work on polymorphisms in genes along biologically
related pathways, and the inclusion of gene × environ-
ment interactions, will necessitate further development of
statistical methods. Currently accepted methods to model
the association between large numbers of variables (both
genetic and non-genetic) and disease risk are plagued with
problems of sparse data, as well as model choice and
uncertainty. When methods robust to these problems are
developed, further examination of the antioxidant activity
pathway via multivariate analyses of gene × gene and gene
× environment interactions can be examined.
Conclusion
Polymorphisms in the GPX-1 and MnSOD genes are asso-
ciated with an increased risk of breast cancer.
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